"These findings indicate a discrepancy in the approval policies between the FDA and EMA and imply either that some patient groups in the USA do not get access to relevant medical treatment, or that some patient groups in the EU are treated with medicine without a positive benefit–risk balance."

https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(23)00357-1/fulltext